Considering that proteins such as Bruton’s tyrosine kinase (BTK) and Syk are also therapeutic targets17,20,21, it is possible that expression levels of other potential therapeutic targets within the BCR signalling pathway may also inform on CLL prognosis. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.